We are live on ! Find out more
AA

AlphaCentric Advisors Portfolio holdings

AUM $100M
This Fund
S&P 500
This Quarter Est. Return
+9.75%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$135M
AUM Growth
-$1.28M
Cap. Flow
-$11.4M
Cap. Flow %
-8.5%
Top 10 Hldgs %
21.49%
Holding
245
New
28
Increased
29
Reduced
140
Closed
15

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$2.85M
2
ATEC icon
Alphatec Holdings
ATEC
+$2.84M
3
INDV icon
Indivior Pharmaceuticals
INDV
+$2.84M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$2.12M
5
APLS
Apellis Pharmaceuticals
APLS
+$1.76M

Top Sells

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$4.17M
2
PCRX icon
Pacira BioSciences
PCRX
+$3.36M
3
PFE icon
Pfizer
PFE
+$3.06M
4
UTHR icon
United Therapeutics
UTHR
+$2.79M
5
QURE icon
uniQure
QURE
+$2.06M

Sector Composition

Rank Sector Weight
1 Healthcare 57.92%
2 Real Estate 14.45%
3 Financials 7.05%
4 Industrials 3.2%
5 Technology 2.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCYC
51
Bicycle Therapeutics
BCYC
$294M
$849K 0.63%
37,500
-22,500
-38% -$519K
ONIT
52
Onity Group
ONIT
$344M
$817K 0.61%
25,567
– –
PEN icon
53
Penumbra
PEN
$12.5B
$777K 0.58%
+4,000
New +$756K
NVDA icon
54
NVIDIA
NVDA
$4.91T
$726K 0.54%
5,981
-28
-0.5% -$3.31K
VALN
55
Valneva
VALN
$511M
$717K 0.53%
118,000
+29,748
+34% +$211K
NUVL
56
DELISTED
Nuvalent
NUVL
$716K 0.53%
+7,000
New +$581K
MLTX icon
57
MoonLake Immunotherapeutics
MLTX
$1.64B
$706K 0.52%
+14,000
New +$656K
CYTK icon
58
Cytokinetics
CYTK
$10.9B
$660K 0.49%
+12,500
New +$697K
PRCT icon
59
Procept Biorobotics
PRCT
$1.09B
$641K 0.48%
8,000
-2,000
-20% -$142K
ARAY icon
60
Accuray
ARAY
$30.8M
$630K 0.47%
350,000
– –
ACAD icon
61
Acadia Pharmaceuticals
ACAD
$4.38B
$615K 0.46%
40,000
-60,000
-60% -$1M
ISRG icon
62
Intuitive Surgical
ISRG
$122B
$614K 0.46%
1,250
-750
-38% -$349K
SYM icon
63
Symbotic
SYM
$5.25B
$610K 0.45%
25,000
+5,000
+25% +$136K
CGNX icon
64
Cognex
CGNX
$10.7B
$608K 0.45%
+15,000
New +$639K
ROK icon
65
Rockwell Automation
ROK
$51.4B
$604K 0.45%
+2,250
New +$597K
SOUN icon
66
SoundHound AI
SOUN
$2.73B
$583K 0.43%
125,000
-25,000
-17% -$121K
HIG icon
67
Hartford Financial Services
HIG
$38.4B
$523K 0.39%
4,451
-202
-4% -$22.1K
EWA icon
68
iShares MSCI Australia ETF
EWA
$1.43B
$522K 0.39%
19,248
-605
-3% -$15.3K
SGMT icon
69
Sagimet Biosciences
SGMT
$483M
$512K 0.38%
185,000
– –
EMBC icon
70
Embecta
EMBC
$193M
$508K 0.38%
36,000
-20,500
-36% -$298K
SNPS icon
71
Synopsys
SNPS
$73.6B
$506K 0.38%
1,000
-1,000
-50% -$537K
VYNE icon
72
VYNE Therapeutics
VYNE
$25.4M
$505K 0.38%
268,485
-42,015
-14% -$79.6K
AVAV icon
73
AeroVironment
AVAV
$7.2B
$501K 0.37%
2,500
-650
-21% -$117K
APGE icon
74
Apogee Therapeutics
APGE
$10.1B
$499K 0.37%
+8,500
New +$407K
BBJP icon
75
JPMorgan BetaBuilders Japan ETF
BBJP
$17.1B
$496K 0.37%
8,363
-260
-3% -$15K
1 2
3
4 5

Similar funds

WCM
Weber Capital Management San Francisco, California $100M AUM
FCM
Fourier Capital Management Hong Kong $100M AUM
BIA
Baer Investment Advisory Corte Madera, California $100M AUM 23.87% 1-Year Est. Return
AGAM
Audent Global Asset Management West Hollywood, California $100M AUM 22.83% 1-Year Est. Return
E
Entelevest Coral Gables, Florida $100M AUM
HCM
Hicks Capital Management Columbus, Ohio $100M AUM 14.29% 1-Year Est. Return
AC
Arrow Capital Sydney, Australia $100M AUM 68.52% 1-Year Est. Return
OIS
OneAscent Investment Solutions Birmingham, Alabama $100M AUM 15.97% 1-Year Est. Return

AlphaCentric Advisors's Q3 2024 Portfolio in Review

As of Q3 2024, AlphaCentric Advisors held 245 positions worth $135M, down 0.95% from $136M the previous quarter. Its ten largest holdings account for 21% of the portfolio.

AlphaCentric Advisors withdrew a net $11.4M in Q3 2024, closing 15 positions and reducing 140 holdings. Its most notable exit was BioCryst Pharmaceuticals, an estimated $4.17M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, down from 60% a quarter earlier, followed by Real Estate and Financials.

Against the trend, AlphaCentric Advisors opened a new position in Merck worth $2.73M.

  • AlphaCentric Advisors's largest Q3 2024 buy was Merck: 24,000 shares worth $2.73M.
  • AlphaCentric Advisors added most to Neurocrine Biosciences in Q3 2024, an estimated $2.12M increase.
  • AlphaCentric Advisors's biggest Q3 2024 reduction was Pfizer, cutting an estimated $3.06M.
  • AlphaCentric Advisors fully exited BioCryst Pharmaceuticals in Q3 2024, selling an estimated $4.17M.
  • AlphaCentric Advisors's ten largest holdings make up 21% of its $135M portfolio in Q3 2024.
  • AlphaCentric Advisors opened 28 new positions and closed 15 in Q3 2024.
  • AlphaCentric Advisors's portfolio value fell 0.95% quarter-over-quarter to $135M.

Based on AlphaCentric Advisors's 13F filing for Q3 2024, filed 30 Oct 2024.